Rasagiline for the symptomatic treatment of fatigue in Parkinson's disease

E-ISSN： 1531-8257|30|13|1825-1830

ISSN： 0885-3185

Source： MOVEMENT DISORDERS, Vol.30, Iss.13, 2015-11, pp. : 1825-1830

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of the safety and tolerability of rasagiline in the treatment of the early stages of Parkinson’s disease

By Viallet François Pitel Séverine Lancrenon Sylvie Blin Olivier

Current Medical Research and Opinion, Vol. 29, Iss. 1, 2013-01 ,pp. : 23-31

Informa Healthcare

Access to resources Recommend Favorite

Rasagiline for the management of Parkinson’’s disease

By Dashtipour Khashayar Chen Jack J Lew Mark F

Therapy, Vol. 5, Iss. 2, 2008-03 ,pp. : 203-214

Future Medicine

Access to resources Recommend Favorite

Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: Possible serotonin syndrome

MOVEMENT DISORDERS, Vol. 28, Iss. 10, 2013-09 ,pp. : 1464-1464

John Wiley & Sons Inc

Access to resources Recommend Favorite

Droxidopa for the Short‐Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B)

MOVEMENT DISORDERS, Vol. 30, Iss. 5, 2015-04 ,pp. : 646-654

John Wiley & Sons Inc

Access to resources Recommend Favorite

TREATMENT OF PARKINSON'S DISEASE IN THE AGED

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 4, Iss. 5, 1956-05 ,pp. : 491-497

John Wiley & Sons Inc

Access to resources Recommend Favorite